Structural analysis of hegelian legal philosophy

El presente artículo pretende llevar a cabo un estudio estructural de la filosofía del derecho hegeliana. Mi intención es, por un lado, estudiar y criticar la lógica del proyecto filosófico-político hegeliano, y por otro, establecer sus vínculos con la filosofía moderna que le precede, en concreto con el idealismo trascendental kantiano.The aim of the following article is to explain Hegel’s logic and legal philosophy. My purpose is, in one hand, to show the logic and structural unity of Hegel’s philosophy, and in the other hand, to search his relations with modern philosophy, especially with Kant’s work.peerReviewe

El idealismo jurídico kantiano : una crítica de la crítica

La intención del presente artículo se concreta en delimitar los fundamentos idealistas de la filosofía del derecho kantiana. Para Kant, deducir una justificación absolutamente racional de la forma de lo jurídico implica vincular esa racionalidad directamente con la idea de libertad. A su vez, esta libertad racional sólo puede resolverse legítimamente en la paz que facilita el estado mediante el vínculo que proporciona el contrato social. Así pues, el orden deductivo de la filosofía jurídica kantiana parte de la razón, para, a través de la voluntad expresada en el contrato, concluir necesariamente en el estado moderno. La finalidad última de este trabajo será examinar el desarrollo argumentativo desplegado por el filósofo de Königsberg e identificar sus posibles desajustes lógicos.The aim of the following article is to identify the idealistic foundation of Kant´s legal philosophy. For Kant, to deduce an absolutely rational statement of his legal theory implies to tie down that rationality directly to the idea of freedom. Furthermore this rational freedom can only be reached through the peace that the state provides with the net the social contract makes possible. Therefore the deductive way of Kant´s legal philosophy sets off from the idea of rationality and arrives necessarily to the modern state conducted by the will content in the social contract. The true purpose of this work is to study the development of Kant´s argument and to be able to identify, if there are any, his logical inconsistencies

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.Whole-brain radiotherapy (WBRT) is the treatment backbone for many patients with brain metastasis; however, its efficacy in preventing disease progression and the associated toxicity have questioned the clinical impact of this approach and emphasized the need for alternative treatments. Given the limited therapeutic options available for these patients and the poor understanding of the molecular mechanisms underlying the resistance of metastatic lesions to WBRT, we sought to uncover actionable targets and biomarkers that could help to refine patient selection. Through an unbiased analysis of experimental in vivo models of brain metastasis resistant to WBRT, we identified activation of the S100A9-RAGE-NF-κB-JunB pathway in brain metastases as a potential mediator of resistance in this organ. Targeting this pathway genetically or pharmacologically was sufficient to revert the WBRT resistance and increase therapeutic benefits in vivo at lower doses of radiation. In patients with primary melanoma, lung or breast adenocarcinoma developing brain metastasis, endogenous S100A9 levels in brain lesions correlated with clinical response to WBRT and underscored the potential of S100A9 levels in the blood as a noninvasive biomarker. Collectively, we provide a molecular framework to personalize WBRT and improve its efficacy through combination with a radiosensitizer that balances therapeutic benefit and toxicity.info:eu-repo/semantics/publishedVersio

Tarbiya : revista de investigación e innovación educativa

Resumen basado en el de la publicaciónSe realiza un breve esbozo sobre algunos elementos especialmente relevantes del Bachillerato Internacional. Se repasan esquemáticamente los principios pedagógicos que sustentan el proyecto educativo, así como el currículum y los sistemas de evaluación, resaltando en cada uno de estos aspectos del Programa del Diploma las cuestiones más relevantes. Finalmente se comparan y comentan, a modo de conclusión, algunas respuestas y soluciones que propone el Bachillerato Internacional con las que plantea el Bachillerato LOE.ES

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

Whole-brain radiotherapy (WBRT) is the treatment backbone for many patients with brain metastasis; however, its efficacy in preventing disease progression and the associated toxicity have questioned the clinical impact of this approach and emphasized the need for alternative treatments. Given the limited therapeutic options available for these patients and the poor understand- ing of the molecular mechanisms underlying the resistance of metastatic lesions to WBRT, we sought to uncover actionable targets and biomarkers that could help to refine patient selection. Through an unbiased analysis of experimental in vivo models of brain metastasis resistant to WBRT, we identified activation of the S100A9–RAGE–NF-κB–JunB pathway in brain metastases as a potential mediator of resistance in this organ. Targeting this pathway genetically or pharmacologically was sufficient to revert the WBRT resistance and increase therapeutic benefits in vivo at lower doses of radiation. In patients with primary mela- noma, lung or breast adenocarcinoma developing brain metastasis, endogenous S100A9 levels in brain lesions correlated with clinical response to WBRT and underscored the potential of S100A9 levels in the blood as a noninvasive biomarker. Collectively, we provide a molecular framework to personalize WBRT and improve its efficacy through combination with a radiosensitizer that balances therapeutic benefit and toxicity